Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Deuremidevir Hydrobromide for Suspension in Hospitalized Infants Infected With Respiratory Syncytial Virus.

NCT06206720 is registered in ClinicalTrials.gov with Vigonvita Life Sciences as lead sponsor.

NCT NCT06206720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06206720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Deuremidevir Hydrobromide for Suspension in Hospitalized Infants Infected With Respiratory Syncytial Virus.
Lead sponsor
Vigonvita Life Sciences
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2024
Completion date
June 16, 2025
Enrollment
60 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus infection